Brief: Sino Biopharmaceutical Says Application For Clinical Trial On TQB3205 Approved By NMPA
11/03/2026 15:11
March 11 (Reuters) - Sino Biopharmaceutical 1177.HK: APPLICATION FOR CLINICAL TRIAL ON TQB3205 "PAN-KRAS INHIBITOR" APPROVED BY NMPA Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up